Filters

RAT ANTI HUMAN HER2/neu Antibody

RAT ANTI HUMAN HER2/neu Antibody size: 200ug 464

Supplier MBS MONO
Price 464
Size 200ug
Also known asHER2/neu
Other names MLN 19, Metastatic lymph node gene 19 protein, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Receptor tyrosine-protein kinase erbB-2, Tyrosine kinase-type cell surface receptor HER2, c-erb B2/neu protein, herstatin, metastatic lymph node gene 19 protein, neuro/glioblastoma derived oncogene homolog (avian), neuroblastoma/glioblastoma derived oncogene homolog, p185erbB2, p185erbB2, proto-oncogene Neu, proto-oncogene c-ErbB-2, receptor tyrosine-protein kinase erbB-2, tyrosine kinase-type cell surface receptor HER2, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, receptor tyrosine-protein kinase erbB-2 isoform b
CategoryAntibodies
SubcategoryMnoclonal antibodies
Gene nameHER2/neu
Gene name synonimsN/A
Other gene names CD340, ERBB2, HER-2, HER-2/neu, HER2, HER2, MLN 19, MLN 19, MLN19, NEU, NEU, NGL, NGL, TKR1, ERBB2
ClonalityMonoclonal
Immunoglobulin isotypeIgG2b
CloneICR52
Host organismRat (Rattus norvegicus)
Species reactivity Due to limited knowledge and inability for testing each and every species, the reactivity of the antibody may extend to other species which are not listed hereby, Human (Homo sapiens)
Specificity and cross-reactivity Since it is not possible to test each and every species our knowledge on the corss reactivity of the antibodies is limited, This particular antibody might cross react with speacies outside of the listed ones, _x000D_Excessive HER2/neu is present in around 20% to 25% of invasive breast cancers, _x000D_HER2/neu is used in conjunction with antibodies recognising both Estrogen and Progesterone receptors, a proto-oncogene expressed at the cell surface of a range of tumour cells, and an increased risk of metastasis, and can help determine whether drugs such as trastuzumab (Herceptin) or lapatinib (Tykerb), and to determine patient prognosis and course of treatment, for the classification of breast cancer tumours, might be beneficial, otherwise known as CD340 and c-ErbB-2, referred to as HER2-positive cancer, which is often associated with poor prognosis, HER2/neu This antibody recognises epitope C of human HER2/neu, _x000D_
Purification methodN/A
Form/AppearancePurified (Purified IgG - liquid)
Concentration0 mg/ml, IgG concentration 1
Storage and shipping If there is a precipitate in the vial we recommend you to briefly microcentrifugate it prior to use, Repeated freeze - thaw cycles may denature the peptide chains of the antibody and therefore should be maximally avoided, Shelf Life: 18 months from date of dispatch, Storage in frost free freezers is not recommended, the antibody should be stored undiluted, Store the antibody at +4 degrees Celsius for short-term storage and at -20 degrees Celsius for long-term
Tested applications:Immunohistology - Frozen (IHC)
PropertiesC, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by MBS mono they should be stored frozen at - 24°
Gene targetHER2/neu
Short nameRAT ANTI HUMAN HER2/neu Antibody
Technique antibodies against human proteins, antibodies for, Antibody
Alternative name sapiens HER2/neu (Antibody to), RAT antibody to H
Alternative techniqueantibodies
Identity 3430
Gene ERBB2
Long gene name erb-b2 receptor tyrosine kinase 2
Synonyms gene NGL
Synonyms gene name v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog) v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Synonyms NEU HER-2 CD340 HER2
Synonyms name neuro/glioblastoma derived oncogene homolog human epidermal growth factor receptor 2
Locus 17q12
Discovery year 2001-06-22
GenBank acession X03363
Entrez gene record 2064
RefSeq identity NM_004448
Classification CD molecules Minor histocompatibility antigens Erb-b2 receptor tyrosine kinases
Havana BLAST/BLAT OTTHUMG00000179300
Locus Specific Databases LRG_724

Subscribe to our Newsletter